Key clinical point: Napabucasin, a STAT3 inhibitor, suppressed tumor growth, exhibiting synergistic effects with doxorubicin in vitro and in vivo.
Major finding: A total of 34% (23/69) of DLBCL patients expressed STAT3 in tumor tissues.
Study details: Multiple DLBCL cell lines were tested in vivo as well as in vitro testing of biochemical effects.
Disclosures: The work was supported by grants from the Chinese government. The authors stated that they had no conflicts.
Li X et al. Cancer Lett. 2020 Aug 14. doi: 10.1016/j.canlet.2020.07.032.